Lirilumab, a novel immunotherapeutic antibody targeting LAG-3, represents a notable advance in immunology. Its evolution began with initial investigations demonstrating LAG-3's role in tumor evasion. Preclinical https://lirilumab-reagent639084.wikicommunications.com/user